Recently [3], we investigated the quality of the anti-tumor CD4+ T cell responses in PC patients undergoing surgical resection, by comparing the anti-carcinoembryonic (CEA) and anti-viral CD4+ T cell immunity. The gene discussed is CEACAM5; the disease is neoplasm.